The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes
Status:
Completed
Trial end date:
2020-01-08
Target enrollment:
Participant gender:
Summary
The study is a randomised double blind placebo control cross over trial with 4 weeks washout
period. The expected duration of participant participation is 103 days. the study aims to
investigate the effect of dapagliflozin, a SGLT2 inhibitor, on glucose flux, lipolysis and
exercise in patients with type 2 diabetes.
Phase:
Phase 4
Details
Lead Sponsor:
University of Leicester
Collaborators:
AstraZeneca Royal Surrey County Hospital NHS Foundation Trust